Penehyclidine inhalation

Phase 3Small molecule

Penehyclidine inhalation is one of 43 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Adverse EventsRecruiting

Nausea and VomitingPreclinical

Active, not recruiting

Adverse EventsPhase 3

Recruiting

Competition

Competitive Landscape

78 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Kytril

CConrado Roberto Hoffmann Filho

Approved

12 2

Ketalar

AAultman Health Foundation

Approved

2 3

Marcaine

IInnocoll

Approved

1 4

Thalomid

Bristol-Myers Squibb

Phase 3

2 5

Abraxane

Bristol-Myers Squibb

Phase 3

1 6

Megace

Bristol-Myers Squibb

Phase 3

1 7

Gemzar

Johnson & Johnson

Phase 3

1 8

Nereus

VVanda Pharmaceuticals

Phase 3

2 9

Penehyclidine inhalation

PPeking University First Hospital

Phase 3

1 10

HSK21542

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Adverse Events

NCT06624696

Clinical

Trials by Indication[1]

Complication1 trial

Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications

Completed·PPeking University First Hospital·Phase 4·NCT02644876·864 enrolled

Penehyclidine1 trial

Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery

Completed·PPeking University First Hospital·Phase 4·NCT03868709·864 enrolled

Nausea and vomiting1 trial

Penehyclidine and Postoperative Nausea and Vomiting After Bimaxillary Surgery

Completed·PPeking University First Hospital··NCT04112771·243 enrolled

Oxidative Stress1 trial

Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients

Unknown status·ZZhujiang Hospital·Phase 4·NCT02202239·60 enrolled

Adverse Events1 trial

Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia

Recruiting·SSun Yat-sen University·Phase 4·NCT06624696·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Penehyclidine inhalation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Penehyclidine inhalation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Penehyclidine inhalation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University First Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking University First Hospital

Penehyclidine inhalation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Complication1 trial

Penehyclidine1 trial

Nausea and vomiting1 trial

Oxidative Stress1 trial

Adverse Events1 trial

References

Drug Info

Quick Facts

Related News